Baillie Gifford & CO Adaptimmune Therapeutics PLC Transaction History

Baillie Gifford & CO

$126 Billion
Q1 2024

A detailed history of Baillie Gifford & CO transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Baillie Gifford & CO holds 15,871,875 shares of ADAP stock, worth $15.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

15,871,875

Previous 15,912,140 0.25%

Holding current value

$15.6 Million

Previous $12.6 Million 99.5%

% of portfolio

0.02%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$0.7 - $1.75 $28,185 - $70,463	-40,265 Reduced 0.25%	15,871,875 $25.1 Million
Q4 2023 Jan 26, 2024	SELL	$0.43 - $0.79 $531,165 - $975,862	-1,235,269 Reduced 7.2%	15,912,140 $12.6 Million
Q3 2023 Nov 13, 2023	SELL	$0.73 - $1.04 $20,969 - $29,875	-28,726 Reduced 0.17%	17,147,409 $13.4 Million
Q2 2023 Jul 28, 2023	BUY	$0.9 - $1.51 $57,719 - $96,840	64,133 Added 0.37%	17,176,135 $15.8 Million
Q1 2023 May 03, 2023	SELL	$1.06 - $2.16 $61,413 - $125,143	-57,937 Reduced 0.34%	17,112,002 $18.7 Million

Q4 2022 Jan 24, 2023	BUY	$1.05 - $2.53 $2.63 Million - $6.34 Million	2,505,003 Added 17.08%	17,169,939 $25.1 Million
Q3 2022 Oct 27, 2022	SELL	$1.06 - $2.41 $695,794 - $1.58 Million	-656,410 Reduced 4.28%	14,664,936 $15.8 Million
Q2 2022 Aug 08, 2022	SELL	$1.33 - $2.28 $78,725 - $134,957	-59,192 Reduced 0.38%	15,321,346 $26 Million
Q1 2022 May 05, 2022	BUY	$1.73 - $4.06 $2.81 Million - $6.59 Million	1,624,186 Added 11.81%	15,380,538 $31.7 Million
Q4 2021 Jan 20, 2022	BUY	$3.5 - $5.68 $3.26 Million - $5.29 Million	931,372 Added 7.26%	13,756,352 $51.6 Million
Q3 2021 Oct 19, 2021	BUY	$3.44 - $6.37 $3.88 Million - $7.19 Million	1,128,061 Added 9.64%	12,824,980 $66.3 Million
Q2 2021 Aug 02, 2021	BUY	$3.86 - $5.78 $885,491 - $1.33 Million	229,402 Added 2.0%	11,696,919 $49.8 Million
Q1 2021 May 06, 2021	BUY	$4.9 - $6.83 $5.44 Million - $7.58 Million	1,109,737 Added 10.71%	11,467,517 $60.9 Million
Q4 2020 Feb 10, 2021	BUY	$4.0 - $9.2 $13.1 Million - $30.2 Million	3,279,717 Added 46.34%	10,357,780 $55.8 Million
Q3 2020 Nov 12, 2020	BUY	$7.66 - $10.78 $13.7 Million - $19.3 Million	1,788,394 Added 33.81%	7,078,063 $56.5 Million
Q2 2020 Aug 12, 2020	BUY	$2.58 - $12.1 $2.41 Million - $11.3 Million	935,646 Added 21.49%	5,289,669 $53 Million
Q1 2020 May 08, 2020	BUY	$1.2 - $4.52 $79,773 - $300,480	66,478 Added 1.55%	4,354,023 $11.8 Million
Q4 2019 Feb 10, 2020	BUY	$0.72 - $1.43 $88,371 - $175,515	122,738 Added 2.95%	4,287,545 $5.15 Million
Q3 2019 Nov 07, 2019	BUY	$1.43 - $3.81 $29,982 - $79,884	20,967 Added 0.51%	4,164,807 $6.29 Million
Q2 2019 Aug 08, 2019	BUY	$3.23 - $5.41 $984,019 - $1.65 Million	304,650 Added 7.94%	4,143,840 $16.7 Million
Q1 2019 May 01, 2019	BUY	$3.63 - $6.06 $506,998 - $846,394	139,669 Added 3.78%	3,839,190 $0
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $1.06 Million - $3.99 Million	281,894 Added 8.25%	3,699,521 $21.3 Million
Q3 2018 Nov 13, 2018	BUY	$8.27 - $13.56 $3.18 Million - $5.21 Million	384,366 Added 12.67%	3,417,627 $46.3 Million
Q2 2018 Jul 17, 2018	BUY	$10.42 - $13.74 $4.88 Million - $6.43 Million	467,852 Added 18.24%	3,033,261 $36 Million
Q1 2018 May 10, 2018	BUY	$7.1 - $11.56 $4.58 Million - $7.45 Million	644,816 Added 33.57%	2,565,409 $28.8 Million
Q4 2017 Feb 13, 2018	BUY	$6.68 - $8.74 $3.62 Million - $4.73 Million	541,289 Added 39.24%	1,920,593 $12.8 Million
Q3 2017 Oct 20, 2017	BUY	$4.93 - $8.93 $276,060 - $500,044	55,996 Added 4.23%	1,379,304 $11.3 Million
Q2 2017 Aug 10, 2017	BUY	N/A	1,323,308	1,323,308 $5.94 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

160M

Call Options Held

42.8K

Put Options Held

42.1K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $160M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Adaptimmune Therapeutics PLC Transaction History